07 April 2025
Boehringer Ingelheim Animal Health (BIAH) is dedicated to improving animal health by understanding the drivers of chronic inflammation in canine periodontitis.
Canine periodontitis is a common oral disease in dogs characterized by inflammation and destruction of the periodontal tissues, leading to tooth loss and potential systemic health implications. The pathogenesis of periodontitis is a complex process that occurs at different speeds depending on factors such as breed, individual dog, and individual tooth. The initial stage of periodontitis is gingivitis, which is reversible but can progress to involve the surrounding tissues in a self-perpetuating manner. Gingivitis is characterized by inflammation of the gum tissue and involves various cellular and molecular mechanisms, including epithelial and stromal cells, pathogen-associated molecular patterns (PAMPs), and immune cells. This complex interplay of factors contributes to the progression from gingivitis to periodontitis and the transition from acute to chronic inflammation in the gingiva.
As part of this latest opnMe call, we invite researchers to collaborate on the identification of key drivers chronic inflammation in canine periodontitis using ex vivo and/or in vitro approaches.
How would you propose to investigate the immune mechanisms essential for disease progression of canine periodontal disease?
Scientists from our Animal Health division will review your proposal. Your ideas will be pursued collaboratively and receive funding of up to 50,000 euros, should you emerge as one of the successful winners of this opnMe call.
Submit your ideas now, as your proposals can only be accepted if they arrive by May 21, 2025, 11:59 pm PST.
No registration required
Subscribe to our newsletter to stay updated as we add new calls for proposals to opnMe.com
About our opn2EXPERTS question:
How would you propose to investigate the immune mechanisms essential for disease progression of canine periodontal disease?
With ambitious questions such as this, we share precisely formulated scientific questions with the research community as part of our opn2EXPERTS program. Together with winning teams, we intend to explore novel solutions for discovery research that will benefit needs of patients.
About opnMe:
opnMe.com, the open innovation portal of Boehringer Ingelheim, fosters science and collaboration initiatives in areas of high unmet medical need. As part of our first pillar, the “Molecules to Order”, we share well-characterized tool compounds free of charge with no IP strings attached. These are complemented by “Molecules for Collaboration” where we offer access to unprecedented, often unpublished molecules, together with an attractive funding package. Interested scientists are invited to submit testable research hypotheses with these assets in novel diseases or combinations. With our “opn2EXPERTS” program, we enlist scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs. Our opn2TALENTS PostDoc grants provide an opportunity for high-caliber talents to pitch their scientific approaches for well-defined research questions to conduct their research at one of our discovery research sites.